October 9, 2025
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device combination for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure.
Read More View full Prescribing Information
October 8, 2025
SQ Innovation Announces FDA Approval of Lasix® ONYU for Treatment of Edema in Heart Failure
SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix® ONYU (furosemide injection) for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure.
Read More View full Prescribing Information
July 14, 2023
FDA Approves Veklury® (Remdesivir) For COVID-19 Treatment In Patients With Severe Renal Impairment, Including Those On Dialysis
FOSTER CITY, Calif.—(BUSINESS WIRE)—Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury® is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease.
Read More View full Prescribing Information
March 17, 2023
Novartis Tafinlar® + Mekinist® approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Basel, March 16, 2023 — Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar® and Mekinist®, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.